Expert Skin Disease Care at One of China's Premier Academic Medical Centers
The Department of Dermatology at Ruijin Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of China's most distinguished dermatology centers, with a national and international reputation for excellence in the diagnosis and management of autoimmune skin diseases, inflammatory dermatoses, skin cancer, and complex dermatological conditions. The department is particularly renowned for its expertise in autoimmune blistering diseases — including pemphigus and bullous pemphigoid — and in the cutaneous manifestations of systemic autoimmune diseases, making it a national referral center for patients with rare and complex skin conditions.
For international patients seeking expert dermatology care in Shanghai — whether for a complex autoimmune skin disease, severe psoriasis, skin cancer, or a rare dermatological condition — Ruijin Hospital's dermatology department represents one of the most compelling destinations in Asia. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey.
About the Department
Ruijin Hospital's dermatology department is a national key clinical specialty operating dedicated inpatient dermatology wards, a comprehensive outpatient dermatology clinic, a dermatopathology laboratory, a phototherapy unit, a laser and aesthetic dermatology service, and subspecialty clinics for autoimmune skin disease, psoriasis, skin cancer, and contact dermatitis. The department's dermatopathology laboratory provides expert histopathological interpretation of skin biopsies, including direct immunofluorescence for autoimmune blistering diseases — essential for the precise diagnosis of pemphigus, bullous pemphigoid, and other immunobullous disorders.
Faculty members publish regularly in leading dermatology and immunology journals including Journal of Investigative Dermatology, British Journal of Dermatology, Journal of the American Academy of Dermatology (JAAD), JAMA Dermatology, and Journal of Autoimmunity.
Conditions Treated
Autoimmune Blistering Diseases
- Pemphigus Vulgaris & Pemphigus Foliaceus — Anti-desmoglein antibody-guided diagnosis; corticosteroids, rituximab, and mycophenolate; monitoring for remission and relapse
- Bullous Pemphigoid — Anti-BP180/BP230 antibody-guided diagnosis; topical and systemic corticosteroids, doxycycline, and dupilumab for refractory disease
- Mucous Membrane Pemphigoid — Multidisciplinary management with ophthalmology and ENT for ocular and mucosal involvement
- Epidermolysis Bullosa Acquisita — Rare autoimmune blistering disease; colchicine, dapsone, and rituximab
- Linear IgA Bullous Dermatosis — Dapsone and corticosteroid therapy
- Dermatitis Herpetiformis — Gluten-free diet and dapsone; celiac disease coordination with gastroenterology
Inflammatory Skin Diseases
- Psoriasis — Mild to severe plaque psoriasis; biologic therapy (IL-17 inhibitors: secukinumab, ixekizumab, bimekizumab; IL-23 inhibitors: guselkumab, risankizumab, tildrakizumab; IL-12/23: ustekinumab; TNF inhibitors); JAK inhibitors (deucravacitinib); phototherapy
- Atopic Dermatitis (Eczema) — Mild to severe AD; dupilumab, tralokinumab, and lebrikizumab for moderate-to-severe disease; JAK inhibitors (abrocitinib, upadacitinib, baricitinib); topical calcineurin inhibitors and PDE4 inhibitors
- Hidradenitis Suppurativa — Adalimumab, secukinumab, and bimekizumab; surgical management coordination
- Urticaria & Angioedema — Chronic spontaneous urticaria; omalizumab for antihistamine-refractory disease
- Contact Dermatitis — Patch testing for allergic contact dermatitis; occupational dermatology
- Rosacea — Medical and laser management
- Alopecia Areata — JAK inhibitors (baricitinib, ritlecitinib) for severe alopecia areata
Connective Tissue Disease & Cutaneous Autoimmunity
- Cutaneous Lupus Erythematosus — Discoid lupus, subacute cutaneous lupus, and lupus profundus; hydroxychloroquine, belimumab, and anifrolumab
- Dermatomyositis — Skin manifestations of dermatomyositis; myositis antibody panel-guided management; IVIG, rituximab, and JAK inhibitors
- Systemic Sclerosis (Skin Manifestations) — Skin fibrosis, Raynaud's phenomenon, and digital ulcers; multidisciplinary management with rheumatology
- Vasculitis (Cutaneous) — Leukocytoclastic vasculitis, IgA vasculitis (Henoch-Schönlein purpura), and cutaneous polyarteritis nodosa
Skin Cancer & Oncological Dermatology
- Melanoma — Dermoscopy-guided diagnosis; surgical excision and sentinel lymph node biopsy coordination; BRAF/MEK inhibitors and PD-1 immunotherapy for advanced disease
- Basal Cell Carcinoma (BCC) — Surgical excision, Mohs micrographic surgery coordination, vismodegib for advanced BCC
- Squamous Cell Carcinoma (SCC) — Surgical excision and cemiplimab for advanced disease
- Merkel Cell Carcinoma — Avelumab and pembrolizumab immunotherapy
- Cutaneous T-Cell Lymphoma (CTCL) — Mycosis fungoides and Sézary syndrome; phototherapy, bexarotene, mogamulizumab, and brentuximab vedotin
- Actinic Keratosis & Field Cancerization — Photodynamic therapy, topical 5-FU, and imiquimod
Other Dermatological Conditions
- Vitiligo — Ruxolitinib cream, phototherapy (NB-UVB), and systemic JAK inhibitors for extensive disease
- Acne Vulgaris & Rosacea — Medical and procedural management including isotretinoin and laser therapy
- Fungal Skin Infections — Onychomycosis, tinea, and invasive cutaneous fungal infections
- Sexually Transmitted Infections (STIs) — Syphilis, gonorrhea, herpes, and HPV-related conditions
- Rare Genodermatoses — Genetic skin disorders including epidermolysis bullosa, ichthyosis, and neurofibromatosis
Leading Specialist
Prof. Zheng Jie (郑捷) — Director, Dermatology
Prof. Zheng Jie is one of China's most eminent dermatologists and a nationally and internationally recognized authority in autoimmune skin diseases, particularly autoimmune blistering diseases and the cutaneous manifestations of systemic autoimmune conditions. As Director of the Department of Dermatology at Ruijin Hospital, she leads one of China's most distinguished dermatology programs.
Prof. Zheng is particularly recognized for her expertise in pemphigus and bullous pemphigoid — rare but potentially life-threatening autoimmune blistering diseases that require specialist diagnosis and management. Her clinical program is a national referral center for these conditions, with extensive experience in rituximab therapy for refractory pemphigus and in the multidisciplinary management of mucous membrane pemphigoid with ocular and mucosal involvement.
Beyond blistering diseases, Prof. Zheng has deep expertise in cutaneous lupus, dermatomyositis, and other autoimmune skin conditions, and works closely with Ruijin's rheumatology department to provide integrated care for patients with overlapping skin and systemic autoimmune disease. Her research on autoimmune skin diseases has been published in leading dermatology and immunology journals, and she has been a key contributor to national guidelines for pemphigus and bullous pemphigoid management in China.
Autoimmune Blistering Disease Program
Ruijin's autoimmune blistering disease program is one of the most experienced in China, providing expert diagnosis and management for patients with pemphigus, bullous pemphigoid, and other rare immunobullous disorders:
Diagnostic Capabilities
- Direct Immunofluorescence (DIF) — Gold standard for autoimmune blistering disease diagnosis; IgG, IgA, IgM, C3, and fibrinogen staining patterns
- Indirect Immunofluorescence (IIF) — Serum antibody detection on monkey esophagus and salt-split skin substrates
- ELISA for Desmoglein 1/3 and BP180/BP230 — Quantitative antibody measurement for disease activity monitoring
- Skin Biopsy & Dermatopathology — Expert histopathological interpretation by dedicated dermatopathologists
Treatment Protocols
- Rituximab for Pemphigus — B-cell depletion therapy as first-line or steroid-sparing treatment; Ruijin has one of China's largest rituximab-treated pemphigus cohorts
- Dupilumab for Bullous Pemphigoid — Novel IL-4/IL-13 blockade for refractory or steroid-dependent BP
- Immunosuppressive Therapy — Mycophenolate, azathioprine, cyclophosphamide, and IVIG for refractory cases
Biologic Dermatology Program
Ruijin's dermatology department has extensive experience with the full range of approved biologic and targeted therapies for inflammatory skin diseases:
- Psoriasis Biologics — IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), IL-23 inhibitors (guselkumab, risankizumab), and ustekinumab; deucravacitinib (TYK2 inhibitor)
- Atopic Dermatitis Biologics — Dupilumab, tralokinumab, lebrikizumab; JAK inhibitors (abrocitinib, upadacitinib, baricitinib)
- Urticaria — Omalizumab for chronic spontaneous urticaria
- Alopecia Areata — Baricitinib and ritlecitinib for severe alopecia areata
- Vitiligo — Ruxolitinib cream and systemic JAK inhibitors
Why International Patients Choose Ruijin Dermatology
- Autoimmune Blistering Disease Expertise — National referral center for pemphigus and bullous pemphigoid with one of China's largest rituximab-treated pemphigus cohorts
- Comprehensive Biologic Program — Full range of approved biologics and JAK inhibitors for psoriasis, atopic dermatitis, urticaria, and alopecia areata
- Integrated Autoimmune Care — Close collaboration with rheumatology for patients with overlapping skin and systemic autoimmune disease
- Expert Dermatopathology — In-house DIF, IIF, and ELISA for precise autoimmune blistering disease diagnosis
- Skin Cancer Expertise — Dermoscopy, surgical management, and access to targeted therapy and immunotherapy for advanced skin cancers
- Cost-Effectiveness — World-class dermatology care at significantly lower cost than equivalent treatment in Western countries
The CMCS Patient Journey
- Initial Inquiry — Share your skin disease history, biopsy reports, immunofluorescence results, antibody levels, and current medications with CMCS.
- Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate dermatologist based on your condition — autoimmune blistering disease, psoriasis, atopic dermatitis, skin cancer, or connective tissue disease.
- Priority Scheduling — We secure a consultation with minimal waiting time.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near Ruijin Hospital, and Shanghai airport transfers.
- On-Site Concierge — Bilingual coordinators accompany you throughout your hospital visits, managing registration, translation, and communication.
- Diagnostic Support — Full coordination of skin biopsy, DIF, antibody testing, and other required investigations.
- Post-Treatment Follow-Up — Biopsy report translation, antibody level monitoring, and remote follow-up coordination after you return home.
Book a Consultation
If you are seeking expert dermatology care in Shanghai — whether for pemphigus, bullous pemphigoid, psoriasis, atopic dermatitis, cutaneous lupus, skin cancer, or another complex skin condition — CMCS can arrange a specialist consultation with Ruijin Hospital's dermatology team.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개